Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s approval for eteplirsen — or Exondys51 — in the US remains one of the most controversial OKs in FDA history, earning a rare label that says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
